SaNOtize, based out of Vancouver, has achieved promising results from Phase II of their trial for a self-administered nasal spray to protect against Covid-19. Their Phase II involved testing in Canada as well as the UK, and has been shown to dramatically reduce the viral load in recipients.
The spray itself works by killing the virus in the upper airways, preventing it from making its way into the lungs.
The clinical protocol of the second phase involved a double blind, placebo-controlled trial of 79 confirmed Covid-19 cases. The early treatment of these cases yielded lower viral loads, even in those patients infected with the new UK variant of the virus (which typically contains a higher viral load.)
The patients treated saw on average a 95% reduction in viral load after just 24 hours (equivalent to a viral log reduction of 1.362.) Within 72 hours the viral load dropped further, resulting in a 99% decrease. No adverse side effects were recorded in this trial, or in the previous Canadaian based trials which involved over 7,000 patients. The trial so far demonstrates promising results, especially when considering the accessibility and portability of a simple, self-administered nasal spray in the fight against Covid-19. The hope is that swift dissemination of the spray will be able to bolster the vaccine efforts in such a way that allows schools, businesses, and society as a whole to open back up again much more quickly than with only the vaccine.
Chief medical investigator of the study’s UK branch, Dr Stephen Winchester said in an interview with Clinical Trials Arena: “This simple portable nasal spray could be highly effective in the treatment of Covid-19 and reducing onward transmission. Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. Simply stated, I think this could be revolutionary.”
Stay Up to Date on Clinical Studies
Citrus is a fully integrated recruitment and retention software that fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.
Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.
Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.
With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.
Check out what our customers have to say about us here.